341006-48-2

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 34137-14-9 methyl 4-hydroxy-3,5-dimethylbenzoate 
• 10570-67-9 4-iodo-2,6-dimethylphenol 
• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 
• 576-26-1 2.6-dimethylphenol 

Downstream Products

• 7498-53-5 4-(methoxycarbonyl)-2,6-dimethylbenzoic acid 
• 944327-02-0 4-(2-tert-butoxycarbonyl-vinyl)-3,5-dimethyl-benzoic acid methyl ester 
• 1011264-54-2 3-(4-cyano-2,6-dimethyl-phenyl)-propionic acid tert-butyl ester 
• 1011264-31-5 3-[4-(N-hydroxycarbamimidoyl)-2,6-dimethyl-phenyl]-propionic acid tert-butyl ester 
• 944326-88-9 4-(2-tert-butoxycarbonyl-ethyl)-3,5-dimethyl-benzoic acid 
• 944327-03-1 4-(2-tert-butoxycarbonyl-ethyl)-3,5-dimethyl-benzoic acid methyl ester 
• 910132-87-5 tert-butyl 3-(2,6-dimethyl-4-carbamoylphenyl)propanoate 
• 910132-86-4 tert-butyl (E)-3-(2,6-dimethyl-4-carbamoylphenyl)acrylate 
• 910132-88-6 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid 
• 861323-61-7 4-(carboxymethyl)-3,5-dimethylbenzoic acid 
• 910470-85-8 2,2-dimethyl-propionic acid 4-[2-(2,2-dimethyl-propionyloxy)-ethyl]-3,5-dimethyl-2-trimethylsilanylethynyl-benzyl ester 
• 910470-88-1 2,2-dimethyl-propionic acid 4-[2-(2,2-dimethyl-propionyloxy)-ethyl]-2-methanesulfonyloxyacetyl-3,5-dimethyl-benzyl ester 
• 910470-86-9 2,2-dimethyl-propionic acid 4-[2-(2,2-dimethyl-propionyloxy)-ethyl]-2-ethynyl-3,5-dimethyl-benzyl ester 
• 910470-87-0 2,2-dimethyl-propionic acid 2-acetyl-4-[2-(2,2-dimethyl-propionyloxy)-ethyl]-3,5-dimethyl-benzyl ester 

Relevant academic research and scientific papers

AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDINE COMPOUNDS

The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS

The invention relates to thiophene derivatives of formula (I) / their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents wherein: A represents *-CO-CH=CH-, *-CO-CH2CH2-, *-CO-CH2-NH-, wherein the sterisks indicate the bond that is linked to the thiophene group of Formula (I) , and R1-R3 are as defined in the claims.

Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists

3-(2,6-Dimethyl-4-carbamoylphenyl)propanoic acid (Dcp), a 2′,6′-dimethyltyrosine analogue containing a carbamoyl group in place of the hydroxyl function and lacking the amino group, was synthesized. The replacement of Tyr1 in an enkephalin analogue and in dynorphin A(1-11)-NH2 with Dcp resulted in the first opioid peptide-derived antagonists that do not contain a phenolic hydroxyl group at the 1-position residue. The cyclic peptide Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH 2 represents a novel, potent μ opioid antagonist.

Total synthesis of pterosines B and C via a photochemical key step

A total synthesis of pterosines B and C is reported. Starting with a fourfold substituted benzene derivative, the introduction of the remaining substituents is mainly based on Sonogashira couplings followed by different transformations of the ethyne moiety. The key step is a photochemical ring-closure of an α-mesyloxy ketone forming the 1-indanone skeleton. Georg Thieme Verlag Stuttgart.

Dehydroamino acids

Compounds of formula 1 and 1-1, wherein R1 is hydrogen, hydroxy, amino or halogen, R2 is hydrogen, hydroxy, or halogen and R3 is hydrogen (Formula 1) or R1 is hydrogen and R2 and R3 taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is R4 R5 are hydrogen, methyl, ethyl or halogen except that R4 r5 cannot both be hydrogen; and 1) B is hydrogen, or lower alkyl; or 2) B is where R6 R7 R8 and R9 are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro; or 3) B is where R10 is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino; 4) B is where X and Y are independently methylene or nitrogen; or 5) B is where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or 6) B is where Y is carbon or nitrogen; or 7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.